SpecialOffer wrote: ↑17/09/2021 12:04
Slucajevi miokarditisa u Izraelu nakon prve, druge i trece doze.
https://www.news-medical.net/news/20210 ... ation.aspx
A signal of these events following mRNA-based vaccination was first identified in Israel in May 2021, where 148 cases of myocarditis were reported within 30 days of immunization, usually following a second dose.
This prompted the Israeli Ministry of Health to issue an investigation into any possible link between these cases of myocarditis and vaccination.
The results pointed to a possible link between the second vaccine dose and the onset of myocarditis among young men aged 16 to 30, with a stronger link identified among those aged 16 to 19.
Following the initial signal in Israel, further cases of myocarditis and pericarditis following mRNA-based vaccination were reported in numerous other countries.
The product information for both the Pfizer-BioNTech and Moderna vaccines was then updated to include myocarditis and pericarditis as an adverse event of unknown frequency in the UK, Europe, and the US.
Results for the UK
In the UK, 7.93 cases of myocarditis and 6.73 cases of pericarditis occurred per million recipients of at least one dose of the Pfizer-BioNTech vaccine. For the Moderna product, the corresponding figures were 2.07 and 1.79 cases per million.
No data were available regarding the age or sex of those reporting the events, or on which vaccine dose either of the events occurred.
The US findings
In the US, 6.47 cases of myocarditis and 3.53 cases of pericarditis were reported per million individuals who had received two doses of the Pfizer-BioNTech vaccine. For the Moderna product, the corresponding figures were 3.65 and 2.69 cases per million.
Of the 968 myocarditis events reported following Pfizer-BioNTech vaccination, 759 (78.4%) occurred in males. Reports of myocarditis were also more frequent in younger age groups, irrespective of gender. Similarly, while pericarditis was more frequently reported among males, this pattern was less pronounced among those older than 40 years.
Similar trends were observed for the Moderna vaccine.
Overall, the majority of both myocarditis and pericarditis events occurred following the second dose of either vaccine.
The European Economic Area
In the European Economic Area, 4.23 cases of myocarditis and 2.87 cases of pericarditis were reported per million individuals who had received at least one dose of the Pfizer-BioNTech vaccine. For the Moderna product, the corresponding figures were 6.15 cases and 3.84 cases per million.
For both mRNA vaccines, 71.56% of the myocarditis events and 53.46% of the pericarditis events were reported to have affected males.
Najlakše je napisati da su slučajevi na nivou statističke greške.
Slučajevi su zaista iznimno rijetki, ali su zabilježeni i neosporni, i pripisani vakcinama.
Ni u kojem slučaju ne želim da probagiram antivaksersku stanu ili nešto slično, samo iznosim činjenice i to ljudi treba da znaju.
Sakrivanje činjenica i laganje samo stvara nepovjerenje i sumnjičavost.